152 related articles for article (PubMed ID: 17667525)
1. Rofecoxib has different effects on chemokine production in colorectal cancer cells and tumor immune splenocytes.
Walmesley AJ; Zweiri J; Christmas SE; Watson AJ
J Immunother; 2007 Sep; 30(6):614-23. PubMed ID: 17667525
[TBL] [Abstract][Full Text] [Related]
2. Growth inhibitory effect of celecoxib and rofecoxib on human colorectal carcinoma cell lines.
Buecher B; Bouancheau D; Broquet A; Bezieau S; Denis MG; Bonnet C; Heymann MF; Jarry A; Galmiche JP; Blottière HM
Anticancer Res; 2005; 25(1A):225-33. PubMed ID: 15816542
[TBL] [Abstract][Full Text] [Related]
3. [Antitumor effects of specific cyclooxygenase inhibitors combined with chemotherapeutic agents on gastric cancer cells in vitro].
Zhu FS; Chen XM; Wang YJ; Zhang X; Feng JX
Zhonghua Zhong Liu Za Zhi; 2007 Mar; 29(3):186-8. PubMed ID: 17649633
[TBL] [Abstract][Full Text] [Related]
4. Cyclooxygenase-2 is a target of KRASD12, which facilitates the outgrowth of murine C26 colorectal liver metastases.
Smakman N; Kranenburg O; Vogten JM; Bloemendaal AL; van Diest P; Borel Rinkes IH
Clin Cancer Res; 2005 Jan; 11(1):41-8. PubMed ID: 15671526
[TBL] [Abstract][Full Text] [Related]
5. Prevention of posterior capsular opacification through cyclooxygenase-2 inhibition.
Chandler HL; Barden CA; Lu P; Kusewitt DF; Colitz CM
Mol Vis; 2007 Apr; 13():677-91. PubMed ID: 17563718
[TBL] [Abstract][Full Text] [Related]
6. [The effects of selective cyclooxygenase-2 inhibitors on the growth of gastric adenocarcinoma].
Liu C; Tang C; Wan X; Wang C; Zhou X
Sichuan Da Xue Xue Bao Yi Xue Ban; 2003 Jul; 34(3):480-3. PubMed ID: 12910695
[TBL] [Abstract][Full Text] [Related]
7. Expression of inflammatory chemokines combined with local tumor destruction enhances tumor regression and long-term immunity.
Crittenden M; Gough M; Harrington K; Olivier K; Thompson J; Vile RG
Cancer Res; 2003 Sep; 63(17):5505-12. PubMed ID: 14500387
[TBL] [Abstract][Full Text] [Related]
8. Prostaglandin E2 inhibits production of the inflammatory chemokines CCL3 and CCL4 in dendritic cells.
Jing H; Vassiliou E; Ganea D
J Leukoc Biol; 2003 Nov; 74(5):868-79. PubMed ID: 12960284
[TBL] [Abstract][Full Text] [Related]
9. The immune tolerance of cancer is mediated by IDO that is inhibited by COX-2 inhibitors through regulatory T cells.
Lee SY; Choi HK; Lee KJ; Jung JY; Hur GY; Jung KH; Kim JH; Shin C; Shim JJ; In KH; Kang KH; Yoo SH
J Immunother; 2009 Jan; 32(1):22-8. PubMed ID: 19307990
[TBL] [Abstract][Full Text] [Related]
10. [Active immunity for anti-colorectal cancer induced by chemokine MCP-3 gene transfection].
Hu JY; Li GC; Zhu JG; Wang WM; Li YH; Zhou GH; Sun QB
Ai Zheng; 2002 May; 21(5):504-8. PubMed ID: 12452041
[TBL] [Abstract][Full Text] [Related]
11. Cyclooxygenase-2 inhibitors down-regulate osteopontin and Nr4A2-new therapeutic targets for colorectal cancers.
Zagani R; Hamzaoui N; Cacheux W; de Reyniès A; Terris B; Chaussade S; Romagnolo B; Perret C; Lamarque D
Gastroenterology; 2009 Oct; 137(4):1358-66.e1-3. PubMed ID: 19549529
[TBL] [Abstract][Full Text] [Related]
12. Cyclooxygenase-2 inhibition prevents migration of colorectal cancer cells to extracellular matrix by down-regulation of matrix metalloproteinase-2 expression.
Leung E; McArthur D; Morris A; Williams N
Dis Colon Rectum; 2008 Mar; 51(3):342-7. PubMed ID: 18228100
[TBL] [Abstract][Full Text] [Related]
13. Use of cyclooxygenase-2 inhibition to enhance the efficacy of immunotherapy.
DeLong P; Tanaka T; Kruklitis R; Henry AC; Kapoor V; Kaiser LR; Sterman DH; Albelda SM
Cancer Res; 2003 Nov; 63(22):7845-52. PubMed ID: 14633712
[TBL] [Abstract][Full Text] [Related]
14. Eotaxin-2 and colorectal cancer: a potential target for immune therapy.
Cheadle EJ; Riyad K; Subar D; Rothwell DG; Ashton G; Batha H; Sherlock DJ; Hawkins RE; Gilham DE
Clin Cancer Res; 2007 Oct; 13(19):5719-28. PubMed ID: 17908961
[TBL] [Abstract][Full Text] [Related]
15. In vitro and in vivo inhibitory effect evaluation of cyclooxygenase-2 inhibitors, antisense cyclooxygenase-2 cDNA, and their combination on the growth of human bladder cancer cells.
Qin J; Yuan J; Li L; Liu H; Qin R; Qin W; Chen B; Wang H; Wu K
Biomed Pharmacother; 2009 Mar; 63(3):241-8. PubMed ID: 18617357
[TBL] [Abstract][Full Text] [Related]
16. Potent cell growth inhibitory effects in hepatitis B virus X protein positive hepatocellular carcinoma cells by the selective cyclooxygenase-2 inhibitor celecoxib.
Xie H; Gao L; Chai N; Song J; Wang J; Song Z; Chen C; Pan Y; Zhao L; Sun S; Wu K; Feitelson MA; Liu J; Fan D
Mol Carcinog; 2009 Jan; 48(1):56-65. PubMed ID: 18506760
[TBL] [Abstract][Full Text] [Related]
17. Prostaglandin E2 production in ovarian cancer cell lines is regulated by cyclooxygenase-1, not cyclooxygenase-2.
Kino Y; Kojima F; Kiguchi K; Igarashi R; Ishizuka B; Kawai S
Prostaglandins Leukot Essent Fatty Acids; 2005 Aug; 73(2):103-11. PubMed ID: 15963707
[TBL] [Abstract][Full Text] [Related]
18. Induction of host protective Th1 immune response by chemokines in Leishmania donovani-infected BALB/c mice.
Dey R; Majumder N; Bhattacharyya Majumdar S; Bhattacharjee S; Banerjee S; Roy S; Majumdar S
Scand J Immunol; 2007 Dec; 66(6):671-83. PubMed ID: 18021365
[TBL] [Abstract][Full Text] [Related]
19. Mechanical analysis of tumor growth regression by the cyclooxygenase-2 inhibitor, DFU, in a Walker256 rat tumor model: importance of monocyte chemoattractant protein-1 modulation.
Muta M; Matsumoto G; Nakashima E; Toi M
Clin Cancer Res; 2006 Jan; 12(1):264-72. PubMed ID: 16397051
[TBL] [Abstract][Full Text] [Related]
20. Combination therapy of S-1 with selective cyclooxygenase-2 inhibitor for liver metastasis of colorectal carcinoma.
Tachimori A; Yamada N; Amano R; Ohira M; Hirakawa K
Anticancer Res; 2008; 28(2A):629-38. PubMed ID: 18507001
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
